A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
GlaxoSmithKline
Takeda
Immunitas Therapeutics
AIDS Malignancy Consortium
Roswell Park Cancer Institute